Open AccessRecent advances in targeted drug delivery for treatment of osteoarthritis
Author(s) -
Shikhar Mehta,
Tengfei He,
Ambika G. Bajpayee
Publication year - 2021
Publication title -
current opinion in rheumatology/current opinion in rheumatology, with evaluated medline
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.452
H-Index - 112
eISSN - 1080-8175
pISSN - 1040-8711
DOI - 10.1097/bor.0000000000000761
Subject(s) - osteoarthritis , medicine , cartilage , drug delivery , inflammation , drug , targeted drug delivery , genetic enhancement , bioinformatics , pharmacology , pathology , nanotechnology , biology , materials science , alternative medicine , anatomy , biochemistry , gene
Osteoarthritis is associated with severe joint pain, inflammation, and cartilage degeneration. Drugs injected directly into intra-articular joint space clear out rapidly providing only short-term benefit. Their transport into cartilage to reach cellular targets is hindered by the tissue's dense, negatively charged extracellular matrix. This has limited, despite strong preclinical data, the clinical translation of osteoarthritis drugs. Recent work has focused on developing intra-joint and intra-cartilage targeting drug delivery systems (DDS) to enable long-term therapeutic response, which is presented here.